Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

计划入组 63 人 · 首次发布于 2003 年 1 月 27 日

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis

计划入组 107 人 · 首次发布于 2018 年 7 月 9 日

(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis

计划入组 251 人 · 首次发布于 2018 年 11 月 6 日

KIT tyrosine kinase activator (inflammatory/autoimmune diseases)

KIT tyrosine kinase activator therapy(Celldex Therapeutics)

Tyrosine(Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10)

C₉H₁₁NO₃

KIT COSMETICS PTY LTD

Australia

BEST DENTAL KIT LLC

United States

Cogent Biosciences

United States

GSK Acquires IDRx for $1 Billion to Advance GIST Treatment

EMA Extends Shelf Life of Veterinary Cancer Drug MASIVET to 48 Months

Abbisko Therapeutics' Pimicotinib Achieves Primary Endpoints in Phase III Study for GIST